The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. ARS Pharmaceuticals Inc shares valued at $9,534,642 were sold by Flynn James E on Nov 11 ’24. At $18.04 per share, Flynn James E sold 528,456 shares. The insider’s holdings dropped to 5,274,735 shares worth approximately $74.27 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Flynn James E sold 34,814 shares, netting a total of over 609,064 in proceeds. Following the sale of shares at $17.49 each, the insider now holds 5,257,328 shares.
Before that, Scott Kathleen D. had sold 12,500 shares from its account. In a trade valued at $200,000, the Chief Financial Officer traded ARS Pharmaceuticals Inc shares for $16.00 each. Upon closing the transaction, the insider’s holdings decreased to 12,500 shares, worth approximately $69681.92.
As published in their initiating research note from Cantor Fitzgerald on August 20, 2024, ARS Pharmaceuticals Inc [SPRY] has been an Overweight. Analysts at Raymond James upgraded the stock from ‘”an Outperform”‘ to ‘”a Strong buy”‘ outlook in a report released in mid August. As of August 12, 2024, Leerink Partners has reiterated its “an Outperform” rating for SPRY. Earlier on July 25, 2024, Raymond James initiated its rating. Their recommendation was “an Outperform” for SPRY stock.
Analyzing SPRY Stock Performance
During the last five days, there has been a drop of approximately -10.43%. Over the course of the year, ARS Pharmaceuticals Inc shares have jumped approximately 156.93%. Shares of the company reached a 52-week high of $18.51 on 11/11/24 and a 52-week low of $5.19 on 01/04/24. A 50-day SMA is recorded $14.53, while a 200-day SMA reached $10.71. Nevertheless, trading volume fell to 3.18 million shares from 1.71 million shares the previous day.
Support And Resistance Levels for ARS Pharmaceuticals Inc (SPRY)
According to the 24-hour chart, there is a support level at 13.08, which, if violated, would cause prices to drop to 12.08. In the upper region, resistance lies at 15.79. The next price resistance is at 17.51. RSI (Relative Strength Index) is 42.24 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.58, which suggests the price will decrease in the coming days. Percent R is at 93.96%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
